Novel anticoagulants
Chair: G. Heusch (Essen), P. O´Gara (Boston, US)
| 11:00 | (V490) | What is the advantage of novel anticoagulants over warfarin? |
| C. Bode (Freiburg im Breisgau) | ||
| 11:15 | Diskussion | |
| 11:20 | (V491) | Role of NOACs in the management of patients following acute coronary syndromes |
| N. N. (N.N.) | ||
| 11:35 | Diskussion | |
| 11:40 | (V492) | Do we have to switch all patients from warfarins on novel anticoagulants? And which one for which patient? |
| F. de Haan (Solingen) | ||
| 11:55 | Diskussion | |
| 12:00 | (V493) | What to do when they bleed? |
| D. May (Lewisville, US) | ||
| 12:15 | Diskussion | |
| 12:20 | Abschlussdiskussion |
| 12:30 - 13:00 | L u n c h - B r e a k |